KRBP insider filings
Kiromic Biopharma, Inc. — 37 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-08-26. Screen KRBP transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for KRBP between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Kiromic Biopharma, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-08-26 | 4 | BERSANI PIETRO — Chief Executive Officer, Director | Purchase (P): 2,500 @ $2.20 · Purchase (P): 988 @ $1.93 | EDGAR |
| 2024-08-21 | 4 | Hungerford Brian — Chief Financial Officer | Purchase (P): 258 @ $2.25 · Purchase (P): 3,742 @ $2.20 | EDGAR |
| 2024-08-14 | 4 | Hungerford Brian — Chief Financial Officer | Purchase (P): 2,000 @ $1.75 | EDGAR |
| 2024-06-13 | 4 | Misajon Pamela — Director | Purchase (P): 1,200 @ $3.30 · Purchase (P): 410 @ $3.24 | EDGAR |
| 2024-06-13 | 4 | Hungerford Brian — CFO | Purchase (P): 1,000 @ $2.60 | EDGAR |
| 2024-06-12 | 4 | Misajon Pamela — Director | Purchase (P): 1,701 @ $2.93 | EDGAR |
| 2024-06-12 | 4 | Hungerford Brian — CFO | Purchase (P): 1,000 @ $3.18 | EDGAR |
| 2024-06-12 | 4 | BERSANI PIETRO — CEO, Director | Purchase (P): 3,000 @ $3.23 · Purchase (P): 3,000 @ $3.28 | EDGAR |
| 2024-06-12 | 4 | NAGEL MICHAEL — Director | Purchase (P): 1,000 @ $3.33 | EDGAR |
| 2024-06-04 | 4 | Ralston Shannon — 10% owner | Purchase (P) @ $2,000,000 | EDGAR |
| 2024-05-07 | 4 | Hungerford Brian — CFO | Grant/award (A): 35,033 @ $0 · Grant/award (A): 21,900 @ $0 · Other (J): 21,900 (derivative) @ $0 | EDGAR |
| 2024-05-07 | 4 | BERSANI PIETRO — CEO, Director | Grant/award (A): 45,968 @ $0 | EDGAR |
| 2024-03-20 | 4 | Catlin Michael — Director | Grant/award (A): 18,000 | EDGAR |
| 2024-03-20 | 4 | Misajon Pamela — Director | Grant/award (A): 18,000 | EDGAR |
| 2024-03-20 | 4 | NAGEL MICHAEL — Director | Grant/award (A): 18,000 | EDGAR |
| 2023-10-06 | 4 | Misajon Pamela — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2023-10-06 | 4 | Catlin Michael — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2023-10-06 | 4 | Hungerford Brian — CFO | Grant/award (A): 21,900 (derivative) @ $0 | EDGAR |
| 2023-10-06 | 4 | BERSANI PIETRO — CEO, Director | Grant/award (A): 65,600 (derivative) @ $0 | EDGAR |
| 2023-10-06 | 4 | NAGEL MICHAEL — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-08-15 | 4 | Dahlbeck Scott — Chief of Staff | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2022-08-15 | 4 | Clark Daniel Grant — Chief Financial Officer | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2022-08-15 | 4 | BERSANI PIETRO — Chief Executive Officer, Director | Grant/award (A): 638,298 @ $0 | EDGAR |
| 2022-07-05 | 4 | Cicchetti Americo — Director | Grant/award (A): 183,600 (derivative) @ $0 | EDGAR |
| 2022-07-05 | 4 | Tirelli Francis X — Director | Grant/award (A): 183,600 (derivative) @ $0 | EDGAR |
| 2022-07-05 | 4 | Reeves Karen — Director | Grant/award (A): 183,600 (derivative) @ $0 | EDGAR |
| 2022-07-05 | 4 | NAGEL MICHAEL — Director | Grant/award (A): 183,600 (derivative) @ $0 | EDGAR |
| 2022-05-25 | 4 | Dahlbeck Scott — Chief Medical Officer | Option exercise (M): 17,240 · Option exercise (M): 17,240 (derivative) @ $0 | EDGAR |
| 2021-09-10 | 4 | Chiriva Internati Maurizio — CHIEF EXECUTIVE OFFICER, Director | Purchase (P): 2,800 @ $3.70 | EDGAR |
| 2021-08-02 | 4 | Ryan Michael Charles — See Remarks | Other (J): 50,189 @ $0 · Other (J): 31,991 (derivative) @ $0 | EDGAR |
| 2021-06-24 | 4 | Rotino Gianluca — CHIEF STRAT & INNOV OFFICER, Director | Grant/award (A): 71,985 (derivative) @ $0 | EDGAR |
| 2021-06-24 | 4 | Nunez Ignacio — CHIEF OPERAT. AND MANUF. OFFI. | Grant/award (A): 17,710 (derivative) @ $0 · Grant/award (A): 147,038 (derivative) @ $0 | EDGAR |
| 2021-05-26 | 4 | Schneider Jerry A. — Director | Purchase (P): 5,000 @ $7.31 | EDGAR |
| 2021-03-11 | 4/A | Rotino Gianluca — CSO AND CIO, Director | Disposition to issuer (D): 4,423 (derivative) @ $0 | EDGAR |
| 2021-03-11 | 4/A | Tontat Tony — CFO AND COO, Director | Disposition to issuer (D): 5,528 (derivative) @ $0 | EDGAR |
| 2021-01-06 | 4 | Tontat Tony — CFO & COO, Director | Grant/award (A): 5,528 (derivative) @ $0 | EDGAR |
| 2021-01-06 | 4 | Rotino Gianluca — See Remarks, Director | Grant/award (A): 4,423 (derivative) @ $0 | EDGAR |
Recent 8-K events — Kiromic Biopharma, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-03-21 | 8-K | 1.03 — Bankruptcy or Receivership 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | EDGAR |
| 2025-03-17 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-02-03 | 8-K/A | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-02-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-09-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-08-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-07-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-06-28 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=KRBP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs